Trial Profile
Phase 1 Clinical Study To Investigate The Safety And Immunogenicity Of The H3N2 (A/Brisbane/10/2007) M2SR Monovalent Influenza Vaccine
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs H3N2 M2SR influenza vaccine-FluGen (Primary)
- Indications Influenza A virus H3N2 subtype
- Focus Adverse reactions; First in man
- Sponsors FluGen
- 13 Nov 2018 Status changed from active, no longer recruiting to completed, based on the results presented at the IDWeek 2018.
- 07 Oct 2018 Results presented at the IDWeek 2018
- 17 Sep 2018 Results published in the Media Release